The real “patent war” isn’t fought in court—it’s fought in the months before the drug goes generic.
Generic entry is often framed as a simple timeline: patent expires, competition arrives, prices fall. But anyone who’s watched the Paragraph IV process …
Why consumers pay a “trust premium” for branded generics—and what it signals for the next phase of pharma competition
In healthcare, the price you pay is rarely just a number. It’s a vote—quietly cast—about risk, reliability, and what you believe will …
Why Consumers Pay a “Trust Premium” for Branded Generics Read Post »
AI is getting better at predicting your drug’s future—whether you’re ready or not.
In pharma, we’ve spent years building competitive moats with data: trial results, label language, patent estates, manufacturing know-how, and payer narratives. But a new…
What AI Knows About Your Drug vs. Your Competitors Read Post »
Most pharma teams don’t lose because they lack data. They lose because they don’t close the loop.
That’s the uncomfortable truth behind the “intelligence gap” many organizations quietly accept: they collect patent information, track filings, and monito…
Read the Patent, Beat the Competition: The Intelligence Gap Most Pharma Teams Leave Open Read Post »
Two Systems, One Fight: How the Patent “Dance” and Orange Book Linkage Are Shaping the $400B Biologics War
The biologics market is entering a new phase of intensity—and it’s not just about science. It’s about timing, leverage, and the choreography of t…
Most teams don’t lose to competitors—they lose to timing.
In pharma, the “race” isn’t only about who discovers the next molecule. It’s about who spots the next opening—the moment exclusivity ends, the moment a patent landscape shifts, the moment a ge…
Find Expired Drug Patents Before Your Competitors Do Read Post »
The patent cliff isn’t a cliff anymore—it’s a battlefield.
For years, the story around “patent expiration” has been told as a simple timeline: the brand exclusivity ends, generics arrive, and the market resets. But the last few years have made that n…
AI is your drug’s new KOL—and you’re not tracking it.
For years, pharma’s “influence map” has been human: key opinion leaders, conference circuits, advisory boards, and the quiet gravity of a respected clinician who can move prescribing behavior. But t…
AI Is Your Drug’s New KOL — and You’re Not Tracking It Read Post »
Most companies don’t miss the patent—they miss the money.
Drug patent expiry is treated like an endpoint: a date on a calendar, a risk in a spreadsheet, a countdown to generic entry. But the real value window often opens before the patent dies—and it…
Drug patent strategy is often treated like a calendar exercise—until it isn’t.
The hook: One missed date can turn a “planned” launch into an unplanned scramble, compressing margins, derailing pipeline sequencing, and forcing portfolio decisions under p…
Get new actionable insights and updates from BiotechBlog
